Every day brings new of “breakthroughs” in biomedical research. Most of these are incremental advances, and many you never hear about again because they couldn’t be replicated, failed in early clinical trials, or some other problem.But as described in this link from Wired, I think this could be real progress for Parkinson’s therapy research. While I’ve checked for all the known risk alleles in genes like SNCA, PINK1, LRRK2, PARK7, etc. in my genome sequence and I don’t have ’em, there are sporadic cases that aren’t associated with specific genetic risk. It looks like there are now new tests–one involving cerebrospinal fluid and one scratch-and-sniff test–that predict Parkinson’s years before the pathological symptoms appear. This will impact drug
Topics:
Joel Eissenberg considers the following as important: advancing pharma research, early detection, Healthcare, Parkinson's disease
This could be interesting, too:
Angry Bear writes The Ageing Population
Bill Haskell writes Are Drug Companies Alone Responsible for the Prices We Pay for Medicines?
Bill Haskell writes When you Leave, Please Put Out the Lights . . .
Angry Bear writes March 2024, Subsidy Enhancements Allow ~ Half of all Enrollees to be Eligible for Free Benchmark ACA Silver Coverage
But as described in this link from Wired, I think this could be real progress for Parkinson’s therapy research. While I’ve checked for all the known risk alleles in genes like SNCA, PINK1, LRRK2, PARK7, etc. in my genome sequence and I don’t have ’em, there are sporadic cases that aren’t associated with specific genetic risk.
It looks like there are now new tests–one involving cerebrospinal fluid and one scratch-and-sniff test–that predict Parkinson’s years before the pathological symptoms appear. This will impact drug discovery for early treatment and prevention, since pharma can now pre-screen for at-risk subjects at clinical trial enrollment.